SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

COAG

Hemab Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed7d 15h ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Monitor enrollment updates and interim data from SOLARA; the single-arm design and FDA's prior recommendation for a randomized trial introduce regulatory risk. Positive Phase 3 results could support a BLA submission and transform Hemab's commercial prospects in GT.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$42.81
T+0 close · Nov 9, 2026 · via day close
Latest settled
−8.77%
T+5 · $39.06
Vs SPY
−7.08%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $42.81entry
  2. T+1 · 7d ago −9.44%α −9.07% · $38.77
  3. T+5 · 16h ago −8.77%α −7.08% · $39.06
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Hemab Therapeutics announced the initiation of SOLARA, a pivotal Phase 3 trial of sutacimig (HMB-001) for prophylactic treatment of Glanzmann thrombasthenia, a rare bleeding disorder with no approved prophylactic therapy. The single-arm, intra-participant controlled trial will enroll ~75 participants, with a 24-week run-in followed by 48 weeks of treatment. The FDA recommended a randomized design but acknowledged feasibility concerns; Hemab proceeded with a single-arm design. The trial builds on Phase 2 data showing a 62% reduction in high-intensity annualized treated bleed rates.

Key Facts

  • First participants consented for SOLARA Phase 3 trial of sutacimig in Glanzmann thrombasthenia (GT)
  • Single-arm, open-label trial with 24-week run-in and 48-week treatment; primary endpoint is annualized treated bleed rate
  • Phase 2 data showed 62% reduction in mean high-intensity annualized treated bleed rate and 92% of participants had reduced treated bleed rates
  • FDA granted Fast Track, Orphan Drug, and Breakthrough Therapy Designations for sutacimig in GT
  • No approved prophylactic treatment currently exists for GT

Financial Impact

First pivotal trial for a potential first-in-class prophylactic therapy in an orphan indication with no approved treatment; market cap $2.1B

revenuer&d expenses

Risk Factors

  • FDA recommended a randomized controlled design; Hemab's single-arm approach may face regulatory hurdles for approval
  • Thromboembolic events observed in Phase 2 at higher exposures; dose selection aims to mitigate but risk remains
  • Small trial size (n=75) and rare disease may limit statistical power and generalizability
  • Document contains text addressed to automated readers (forward-looking statements boilerplate)

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398220

Track record

19 reports on COAG

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Viewing Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
  5. Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
  6. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
  7. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
  8. Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
  9. May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
  10. May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens Wed (10h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026